Circulating TP53 Mutations Are Predictive and Prognostic Biomarkers in Pancreatic Cancer Patients Treated with FOLFIRINOX Chemotherapy

HPB, vol. 23, pp. S681

Authors 11

1. Fleur van der Sijde

   Erasmus MC

   Affiliation as printed

   Erasmus MC, University Medical Center Rotterdam, Surgery, the Netherlands

2. Marc G. Besselink

   Amsterdam University Medical Centers · Cancer Center Amsterdam · University of Amsterdam

   Affiliation as printed

   Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Surgery, the Netherlands

3. Jan Willem de Groot

   Isala

   Affiliation as printed

   Isala Hospital, the Netherlands

4. Brigitte C.M. Haberkorn

   Maasstad Ziekenhuis

   Affiliation as printed

   Maasstad Hospital, Medical Oncology, the Netherlands

5. Marjolein Y.V. Homs

   Erasmus MC

   Affiliation as printed

   Erasmus MC, University Medical Center Rotterdam, Medical Oncology, the Netherlands

6. Saskia A. C. Luelmo Aachen

   Leiden University Medical Center

   Affiliation as printed

   Leiden University Medical Center, Medical Oncology, the Netherlands

7. Leonie J. Mekenkamp

   Medisch Spectrum Twente

   Affiliation as printed

   Medisch Spectrum Twente, Medical Oncology, the Netherlands

8. Dana A. M. Mustafa

   Erasmus MC

   Affiliation as printed

   Erasmus MC, University Medical Center Rotterdam, Pathology, Tumor Immuno-Pathology Laboratory, the Netherlands

9. Johanna W. Wilmink

   Amsterdam University Medical Centers · Cancer Center Amsterdam · University of Amsterdam

   Affiliation as printed

   Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Medical Oncology, the Netherlands

10. Casper H.J. van Eijck

    Erasmus MC

    Affiliation as printed

    Erasmus MC, University Medical Center Rotterdam, Surgery, the Netherlands

11. Eveline E. Vietsch

    Erasmus MC

    Affiliation as printed

    Erasmus MC, University Medical Center Rotterdam, Surgery, the Netherlands